Answers are grounded in this paper and cite their sources.
Drug discovery often fails due to unpredictable ADMET issues, which account for 30% of clinical setbacks. Conventional methods lack the atomistic detail needed to navigate the “Avoid-ome”—a finite set of proteins acting as “anti-targets”. OpenADMET is an open-science initiative addressing this by creating pre-competitive, mechanistic datasets. Using high-throughput structural biology, active learning, and community challenges, it builds generalizable models grounded in structural “ground truth”. By directly studying the Avoid-ome, OpenADMET facilitates an era of rational, multi-parameter drug design.
No takes yet. Share an insight, caveat, or question.
Fraser et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: